UIC-2016-049 – 23 aa peptide derived from kinesin KIF13B inhibits angiogenesis: novel therapy for ischemic diseases

The process of angiogenesis is critical to the progression of cancer, eye degeneration, and ischemic diseases. The ability to inhibit defective blood vessel growth could substantially help patients and together the anti-angiogenesis space. Anti-angiogenesis space within the oncology and ophthalmology markets is growing and currently valued at $18 billion. The current anti-angiogenesis therapeutics use small molecules that inhibit the VEGF receptor (VEGFR) itself. UIC inventors uncovered a novel mechanism to inhibit angiogenesis through targeting the process of VEGFR trafficking to the membrane from the Golgi apparatus. The protein responsible for this trafficking is KIF13B, and the inventors have developed a peptide inhibitor to this protein that drastically reduces angiogenesis. This therapeutic will provide an alternative to standard anti-angiogenesis therapies that could increase potency and reduce side effects Veronica Haywood vhaywo2@uic.otm.edu 312-996-4865

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More